

# Different routes to join and partner with IMI2

**Irene Norstedt**  
Head of Unit – Innovative and Personalised Medicine  
DG RTD, European Commission

**Magda Chlebus**  
Director Science Policy, EFPIA

# IMI – Europe's partnership for health

## IMI1 programme 2008-2013


- €2 bn budget
- 11 Calls for proposals
- 60+ projects

---

## IMI2 programme 2014-2024


- Larger budget
- Ambitious Strategic Research Agenda
- Open to other industries

IMI2 total budget  
**€3.28 bn**



# 1. Participant in IMI2 projects

**IMI2 total budget  
€3.28 bn**



# 1. Participant in IMI2 projects


- **Any entity carrying out work relevant to the IMI2 objectives may participate, provided that:**
  - At least three legal entities, each established in a different Member State or an associated country (minimum condition for standard collaborative actions)
  - Potential additional conditions in the annual work plan (and Call documents) are fulfilled

# 1. Participant in IMI2 projects

- **Only beneficiaries established in a EU Member State / H2020 Associated Country are eligible for EU funding, unless:**
  - Participation is deemed essential by the JU for carrying out the action, or
  - Additional conditions are set in the annual Work Plan/Calls documents
- **More types of entities are eligible for EU funding under IMI2 than under IMI1:**
  - Academic institutions
  - Research organisations
  - Small & medium-sized enterprises (SMEs)
  - NEW: **Mid-sized enterprises ( $\leq 500M$ )**
  - Non-profit patient organisations
  - Non-profit public bodies and intergovernmental organisations including specialised agencies

## 2. IMI2 Associated Partner

**IMI2 total budget  
€3.28 bn**



## 2. IMI2 Associated Partner

- **IMI2 is open to participation from organisations beyond the pharmaceutical companies represented by EFPIA**
  - ICT, diagnostics, imaging, animal health, etc.
- **Any legal entity other than a Member or a constituent/affiliated entity of a Member, may apply to join IMI2 as an Associated Partner**
  - Entity **supporting the objectives of the IMI2 Joint Undertaking** in its specific area of research;
  - Upon acceptance of the IMI2 Statutes by a **letter of endorsement**, that details the scope of the association in terms of contribution (in-kind or in-cash), activities and duration;
  - Application to be addressed **to the IMI2 Governing Board**

## 2. Examples


- **Associated Partners:**

- Call 1, topic 1 "Translational approaches to disease modifying therapy of Type 1 Diabetes Mellitus (T1DM)"
  - The **Juvenile Diabetes Research Foundation (JDRF)** will contribute €2.8 million
  - **Leona M. and Harry B. Helmsley Charitable Trust** will contribute a further €2.2 million
- Up-coming call 3: **Bill and Melinda Gates Foundation** will contribute to a topic on Pertussis Vaccination research



## 3. EFPIA direct or indirect Member

IMI2 total budget  
€3.28 bn



# IMI2 vision – towards integrated healthcare solutions

- \* Addressing **healthcare priorities** identified by the WHO 2013 report
- \* Strategic Research Agenda aimed at progressing the vision of **stratified medicines: prevention, treatment and health management**
- \* Entire product cycle **from discovery, through development to healthcare delivery and access models**
- \* **Collaboration across sectors** to harness all knowledge and technologies which can contribute to IMI2 vision - diagnostics, imaging, IT, medical devices, ...

# Engaging in IMI2 activities as EFPIA director or indirect member

- \* Affiliated entities of an EFPIA corporate member, EFPIA specialized group (Vaccines Europe or EBE) or member of an EFPIA association
- \* and EFPIA Partner in Research
  - \* Non-pharmaceutical companies, e.g. imaging, medical information technology, diagnostic, animal health industries, ...
  - \* GE HealthCare, Zeiss, Zoetis, PMB Alcen, Alcediag joined in 2014

	EFPIA Partners in Research	IMI Associated Partners
Impact on IMI2 strategy	Yes <sup>[1]</sup>	No
Access to and impact on the shape of IMI initiatives	Programme level and/or project-by-project	Project-by-project
Impact on IMI governance	Yes <sup>[2]</sup>	No
Contribution to IMI administrative costs	Yes <sup>[3]</sup>	No
Impact on EFPIA research and life science policy	Yes	No
Access to industry support group (Industry Liaison Group)	Yes	No
EU budget available to match industry contributions until 2024	1,425 mln	213 mln
Ability to run sectorial projects (without pharmaceutical industry)	Yes - for developing tools necessary in other IMI projects	Yes
Ability to contribute to ongoing IMI1 projects with EU matching funding for public partners	Yes, with IMI matching (if budget available)	Yes, but without IMI matching

<sup>[1]</sup> Through thematic Strategic Governing Groups and/or RDG

<sup>[2]</sup> Through EFPIA - contribution to “one industry voice” expressed by industry representation on IMI Governing Board

<sup>[3]</sup> 3% of company contribution with minimum contribution of 5, 10 or 20 K depending on European sales and cap set at the level of comparable size EFPIA company

# Interested to get more information?

\* EFPIA Partner in Research

Contact: [magda.chlebus@efpia.eu](mailto:magda.chlebus@efpia.eu) &  
[katharina.angrosch@efpia.eu](mailto:katharina.angrosch@efpia.eu)

## 4. IMI2 Member

- **According to the Statutes of IMI2:** "Any legal entity that directly or indirectly supports research and innovation in a Member State or in a country associated with the Horizon 2020 Framework Programme may apply to become a Member of the IMI2 Joint Undertaking."
- Application to be addressed **to the IMI2 Governing Board** accompanied by a proposal to adapt the composition of the Governing Board

## Key messages

- **IMI2 expands the scope of IMI1 to cover the entire medical research and innovation value chain**
- **Involving all relevant partners: pharmaceutical and other health-related industries, patients, academia, SMEs, regulators, in open innovation networks**
  - Open to participation from industries beyond the pharmaceutical companies
  - More entities eligible for EU funding: medium-sized industrial partners (annual sales less than €500 million)